Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 8/20 | 0.36 |
| ▸ | MAOA | P21397 | 5/20 | 0.36 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.32 |
| ▸ | RAB9A | P51151 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7718358 | 0.84 | KDM4E (0.43) | SMN1; SMN2 | |
| SCHEMBL6894962 | 0.83 | MAOA (0.40) | SLC6A7MAOBMAOANPC1RAB9A | |
| SCHEMBL4011301 | 0.79 | GPR119 (0.46) | POLB | |
| SCHEMBL4317802 | 0.74 | MAOA (0.40) | MAOBMAOANPC1RAB9ATDP1 | |
| SCHEMBL4317148 | 0.72 | KDM4E (0.41) | NPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL4328938 | 0.72 | PDGFRB (0.47) | NPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL4316239 | 0.69 | GRM1 (0.36) | LIMK2NPC1RAB9A | |
| SCHEMBL4757742 | 0.68 | ALDH1A1 (0.47) | SLC6A7MAOBSMN1; SMN2 | |
| SCHEMBL14632808 | 0.68 | MAPT (0.56) | SLC6A7POLB | |
| SCHEMBL28534918 | 0.67 | ACACB (0.46) | NPC1RAB9ASMN1; SMN2POLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020103204-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103204-A1 | Novel compounds and their use | HTR2C, HTR1A, HTR1B | SLC6A7 535/4885MAOB 123/4885MAOA 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.